Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Issue 14 (6th December 2021)

• Record Type: Journal Article
• Authors: Bewersdorf, Jan Philipp; Derkach, Andriy; Gowda, Lohith; Menghrajani, Kamal; DeWolf, Susan; Ruiz, Josel D.; Ponce, Doris M.; Shaffer, Brian C.; Tamari, Roni; Young, James W.; Jakubowski, Ann A.; Gyurkocza, Boglarka; Chan, Alexander; Xiao, Wenbin; Glass, Jacob; King, Amber C.; Cai, Sheng F.; Daniyan, Anthony; Famulare, Christopher; Cuello, Bernadette M.; Podoltsev, Nikolai A.; Roshal, Mikhail; Giralt, Sergio; Perales, Miguel-Angel; Seropian, Stuart; Cho, Christina; Zeidan, Amer M.; Prebet, Thomas; Stein, Eytan M.; Tallman, Martin S.; Goldberg, Aaron D.; Stahl, Maximilian;
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 14(2021)
• Page Start: 3394
• Page End: 3401
• Publication Date: 2021-12-06
• Subjects: Acute myeloid leukemia -- AML -- MDS -- venetoclax -- transplant; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2021.1966788
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: The role of allogeneic hematopoietic cell transplant (allo-HCT) as consolidation after initial venetoclax therapy and the efficacy of venetoclax salvage therapy for relapse after allo-HCT in patients with acute myeloid leukemia (AML) are unclear. We conducted a retrospective study of patients with AML or myelodysplastic syndrome (MDS) who received venetoclax either before or after allo-HCT at Memorial Sloan Kettering Cancer Center and Yale University from 11 August 2016 to 16 November 2020. Among 39 heavily pretreated patients who received venetoclax before allo-HCT, median OS from allo-HCT was not reached after a median follow up of 12.5 months resulting in a 12-month OS estimate of 79.0%. In 37 patients who had received venetoclax-based combinations as salvage therapy after allo-HCT, the overall response rate was 32% with a median OS of 4.7 months (12-month OS estimate: 43.4%). Four patients underwent a second allo-HCT following venetoclax-based salvage therapy suggesting it as a potential salvage treatment option.